Amyotrophic Lateral Sclerosis
EMEA Recommends Orphan Drug Designation for AX200 for the Treatment of Amyotrophic Lateral Sclerosis
Published in Medical Letter on the CDC and FDA, March 2nd, 2008
ALS is a progressive neurodegenerative disease caused by the degeneration of nerve cells innervating skeletal muscles and affects an estimated 50,000 to 100,000 people in the industrialized nations. Patients with ALS suffer from progressive muscle wasting throughout their bodies resulting in increasing disabilities and their lifespan is cut short. Death in ALS patients normally occurs...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Malaria
Fake antimalarial drugs analysis highlights threat to global health - Innovations Facial Plastic Surgery
Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles - Metabolism
Marshfield Clinic Discovers Gene Variant Which Will Significantly Enhance the Accuracy of Molecular Tests for Warfarin Metabolism - Regulatory Actions
Edgeline Holdings Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000 - Valeant Pharmaceuticals International
Valeant Pharmaceuticals Reports Positive Phase III Results for Retigabine in RESTORE 1 - Diabetes Clinical Trial
Data on diabetes clinical trial reported by researchers at NHS Foundation Trust - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
